The antibodies targeting CD47 and SIRPα, either alone or in combination with tumor cell-specific opsonizing antibodies and T-cell checkpoint inhibitors, have shown promise in several trials for various malignancies (23–26). The gene discussed is CD47; the disease is neoplasm.